Aurinia and Vornado Executives Make Significant Stock Purchases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy AUPH?
Source: NASDAQ.COM
- Aurinia Executive Purchase: Kevin Tang of Aurinia Pharmaceuticals made a significant purchase of 900,000 shares of AUPH at $14.10 each on Tuesday, totaling $12.69 million, and was up approximately 5.9% at the peak of the trading session, reflecting confidence in the company's future performance.
- Historical Purchase Review: Prior to this latest buy, Tang had purchased AUPH shares on two other occasions over the past year, spending a total of $26.30 million at an average cost of $9.07 per share, indicating his sustained optimism regarding the company's long-term value.
- Vornado Purchase Details: On the same day, Daniel R. Tisch acquired 155,000 shares of Vornado Realty Trust at $26.91 each, amounting to $4.17 million, and was up about 4.4% at the high point of the trading session, showcasing confidence in the real estate market.
- Vornado Historical Buying: Before this transaction, Tisch had made another purchase in the past twelve months, buying 696,250 shares at $27.85 each, demonstrating his ongoing investment commitment and optimistic outlook for the company's future market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUPH
Wall Street analysts forecast AUPH stock price to rise
6 Analyst Rating
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 14.370
Low
13.00
Averages
16.50
High
21.00
Current: 14.370
Low
13.00
Averages
16.50
High
21.00
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurinia and Vornado Executives Make Significant Stock Purchases
- Aurinia Executive Purchase: Kevin Tang of Aurinia Pharmaceuticals made a significant purchase of 900,000 shares of AUPH at $14.10 each on Tuesday, totaling $12.69 million, and was up approximately 5.9% at the peak of the trading session, reflecting confidence in the company's future performance.
- Historical Purchase Review: Prior to this latest buy, Tang had purchased AUPH shares on two other occasions over the past year, spending a total of $26.30 million at an average cost of $9.07 per share, indicating his sustained optimism regarding the company's long-term value.
- Vornado Purchase Details: On the same day, Daniel R. Tisch acquired 155,000 shares of Vornado Realty Trust at $26.91 each, amounting to $4.17 million, and was up about 4.4% at the high point of the trading session, showcasing confidence in the real estate market.
- Vornado Historical Buying: Before this transaction, Tisch had made another purchase in the past twelve months, buying 696,250 shares at $27.85 each, demonstrating his ongoing investment commitment and optimistic outlook for the company's future market performance.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported Q4 2025 adjusted earnings of $0.26 per share, surpassing analysts' expectations of $0.22 and significantly up from $0.01 a year earlier, indicating a notable improvement in profitability.
- Strong Revenue Growth: The company achieved Q4 revenue of $77.1 million, up from $59.9 million year-over-year and exceeding Wall Street's forecast of $74.8 million, demonstrating robust sales driven by Lupkynis.
- Cautious 2026 Outlook: Although management guided for total revenue of $315 million to $325 million in 2026, reflecting an 11% to 15% growth rate, this forecast falls slightly short of the $327 million consensus from Wall Street, raising investor concerns about future growth.
- Share Buyback Program: Aurinia utilized its improved cash flow to repurchase 12.2 million shares for $98.2 million, ending the year with $398 million in cash and investments, showcasing proactive capital management strategies.
See More
Aurinia Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Outlook
- Significant Sales Growth: Aurinia Pharmaceuticals reported LUPKYNIS sales of $74.2 million in Q4 2025, a 29% year-over-year increase, with expectations for 2026 sales between $305 million and $315 million, reflecting strong market demand and product competitiveness.
- Outstanding Financial Performance: Total revenue for Q4 2025 reached $77.1 million, up 29%, with net income soaring to $210.8 million, a staggering 14,957% increase from 2024, primarily driven by the release of a valuation allowance on deferred tax assets, indicating a substantial improvement in the company's financial health.
- Accelerated R&D Progress: Aurinia has initiated a clinical study of aritinercept for one autoimmune disease and plans to start another study in the first half of 2026, demonstrating the company's ongoing commitment to drug development and strategic positioning in the market.
- Stable Market Strategy: CEO Greenleaf reiterated that the company's strategy for LUPKYNIS remains consistent with the past 6 to 12 months, focusing on leveraging clinical data and updated diagnostic guidelines to drive sales growth and enhance market share, reflecting confidence in future market opportunities.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Aurinia Pharmaceuticals reported an adjusted EPS of $1.53 for Q4, significantly exceeding Wall Street's expectation of $0.22, indicating a strong improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved $77.1 million in revenue for Q4, surpassing the anticipated $74.7 million, demonstrating robust market performance that may attract more investor interest in its future prospects.
- 2026 Revenue Guidance Miss: Despite the strong Q4 results, Aurinia's revenue guidance for 2026 ranges from $315 million to $325 million, falling short of the consensus estimate of $326.8 million, which could raise concerns about the company's future growth trajectory.
- Positive Market Sentiment: Retail sentiment on Stocktwits for Aurinia Pharmaceuticals trended bullish with high message volumes, indicating that investors are optimistic about the company's outlook, potentially driving further stock price increases.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported a Q4 GAAP EPS of $1.53, surpassing expectations by $1.31, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $77.1 million, a 28.8% year-over-year increase, exceeding expectations by $2.4 million, reflecting strong market demand for its products and solidifying its market position.
- Strong Cash Flow: For the three and twelve months ended December 31, 2025, cash flows from operating activities were $45.7 million and $135.7 million, respectively, up 52% and 206% compared to 2024, demonstrating significant operational efficiency improvements.
- Increased Competitive Pressure: Despite Aurinia's strong financial performance, intensifying market competition may pose challenges to future growth, prompting investors to monitor industry dynamics to assess potential risks.
See More
Aurinia Pharma to Announce Q4 Earnings on February 26
- Earnings Announcement: Aurinia Pharma is set to release its Q4 2024 earnings report on February 26 before market open, with a consensus EPS estimate of $0.22, a significant increase from $0.01 in the same quarter last year, indicating improved profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $74.7 million, reflecting a 24.8% year-over-year increase, which showcases Aurinia's competitive position and rising product demand, potentially boosting investor confidence.
- Strong Performance Record: Over the past year, Aurinia has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating financial stability and effective management execution, which may attract further investment.
- Increasing Competitive Pressure: Despite Aurinia's strong performance, market analysts note that competitive threats are rising, which could impact future market share and profitability, prompting investors to monitor industry trends for potential risks.
See More
Aurinia and Vornado Executives Make Significant Stock Purchases
- Aurinia Executive Purchase: Kevin Tang of Aurinia Pharmaceuticals made a significant purchase of 900,000 shares of AUPH at $14.10 each on Tuesday, totaling $12.69 million, and was up approximately 5.9% at the peak of the trading session, reflecting confidence in the company's future performance.
- Historical Purchase Review: Prior to this latest buy, Tang had purchased AUPH shares on two other occasions over the past year, spending a total of $26.30 million at an average cost of $9.07 per share, indicating his sustained optimism regarding the company's long-term value.
- Vornado Purchase Details: On the same day, Daniel R. Tisch acquired 155,000 shares of Vornado Realty Trust at $26.91 each, amounting to $4.17 million, and was up about 4.4% at the high point of the trading session, showcasing confidence in the real estate market.
- Vornado Historical Buying: Before this transaction, Tisch had made another purchase in the past twelve months, buying 696,250 shares at $27.85 each, demonstrating his ongoing investment commitment and optimistic outlook for the company's future market performance.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported Q4 2025 adjusted earnings of $0.26 per share, surpassing analysts' expectations of $0.22 and significantly up from $0.01 a year earlier, indicating a notable improvement in profitability.
- Strong Revenue Growth: The company achieved Q4 revenue of $77.1 million, up from $59.9 million year-over-year and exceeding Wall Street's forecast of $74.8 million, demonstrating robust sales driven by Lupkynis.
- Cautious 2026 Outlook: Although management guided for total revenue of $315 million to $325 million in 2026, reflecting an 11% to 15% growth rate, this forecast falls slightly short of the $327 million consensus from Wall Street, raising investor concerns about future growth.
- Share Buyback Program: Aurinia utilized its improved cash flow to repurchase 12.2 million shares for $98.2 million, ending the year with $398 million in cash and investments, showcasing proactive capital management strategies.
See More
Aurinia Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Outlook
- Significant Sales Growth: Aurinia Pharmaceuticals reported LUPKYNIS sales of $74.2 million in Q4 2025, a 29% year-over-year increase, with expectations for 2026 sales between $305 million and $315 million, reflecting strong market demand and product competitiveness.
- Outstanding Financial Performance: Total revenue for Q4 2025 reached $77.1 million, up 29%, with net income soaring to $210.8 million, a staggering 14,957% increase from 2024, primarily driven by the release of a valuation allowance on deferred tax assets, indicating a substantial improvement in the company's financial health.
- Accelerated R&D Progress: Aurinia has initiated a clinical study of aritinercept for one autoimmune disease and plans to start another study in the first half of 2026, demonstrating the company's ongoing commitment to drug development and strategic positioning in the market.
- Stable Market Strategy: CEO Greenleaf reiterated that the company's strategy for LUPKYNIS remains consistent with the past 6 to 12 months, focusing on leveraging clinical data and updated diagnostic guidelines to drive sales growth and enhance market share, reflecting confidence in future market opportunities.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Aurinia Pharmaceuticals reported an adjusted EPS of $1.53 for Q4, significantly exceeding Wall Street's expectation of $0.22, indicating a strong improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved $77.1 million in revenue for Q4, surpassing the anticipated $74.7 million, demonstrating robust market performance that may attract more investor interest in its future prospects.
- 2026 Revenue Guidance Miss: Despite the strong Q4 results, Aurinia's revenue guidance for 2026 ranges from $315 million to $325 million, falling short of the consensus estimate of $326.8 million, which could raise concerns about the company's future growth trajectory.
- Positive Market Sentiment: Retail sentiment on Stocktwits for Aurinia Pharmaceuticals trended bullish with high message volumes, indicating that investors are optimistic about the company's outlook, potentially driving further stock price increases.
See More
Aurinia Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Beat: Aurinia Pharmaceuticals reported a Q4 GAAP EPS of $1.53, surpassing expectations by $1.31, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $77.1 million, a 28.8% year-over-year increase, exceeding expectations by $2.4 million, reflecting strong market demand for its products and solidifying its market position.
- Strong Cash Flow: For the three and twelve months ended December 31, 2025, cash flows from operating activities were $45.7 million and $135.7 million, respectively, up 52% and 206% compared to 2024, demonstrating significant operational efficiency improvements.
- Increased Competitive Pressure: Despite Aurinia's strong financial performance, intensifying market competition may pose challenges to future growth, prompting investors to monitor industry dynamics to assess potential risks.
See More
Aurinia Pharma to Announce Q4 Earnings on February 26
- Earnings Announcement: Aurinia Pharma is set to release its Q4 2024 earnings report on February 26 before market open, with a consensus EPS estimate of $0.22, a significant increase from $0.01 in the same quarter last year, indicating improved profitability.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $74.7 million, reflecting a 24.8% year-over-year increase, which showcases Aurinia's competitive position and rising product demand, potentially boosting investor confidence.
- Strong Performance Record: Over the past year, Aurinia has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating financial stability and effective management execution, which may attract further investment.
- Increasing Competitive Pressure: Despite Aurinia's strong performance, market analysts note that competitive threats are rising, which could impact future market share and profitability, prompting investors to monitor industry trends for potential risks.
See More
